Výsledky vyhledávání - "R. A. Beckman"

Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients With Advanced Ovarian Cancer

Autor: C. W. Whitney, G. A. Ross, S. Z. Fields, R. A. Beckman, J. H. Malfetano, Daniel L. Clarke-Pearson, S. R. Lane, M. H. DeWitte, Timothy Iveson, P. Hanjani, L. Van Le, Gunnar B. Kristensen

Publikováno v: Journal of Clinical Oncology. 19:3967-3975

PURPOSE: To evaluate oral topotecan as single-agent, second-line therapy in patients with ovarian cancer previously treated with a platinum-based regimen. PATIENTS AND METHODS: Patients (N = 116) received oral topotecan 2.3 mg/m2 daily for 5 days eve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65d7602426b3fd3915c4432532b8463
https://doi.org/10.1200/jco.2001.19.19.3967

Zobrazit plný text záznamu

Recovery from ocular ischemic syndrome after treatment with verapamil

Autor: J M, Winterkorn, R L, Beckman

Publikováno v: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 15(4)

Vasospasm has been implicated as a cause of amaurosis fugax, which can be controlled by administration of the calcium channel blockers nifedipine or verapamil. However, vasospasm has not previously been thought to be involved in chronic ocular ischem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::562aecb662a3ebdc3afbe985641b84e3
https://pubmed.ncbi.nlm.nih.gov/8748556

Zobrazit plný text záznamu

Bandage contact lens augmentation of 5-fluorouracil treatment in glaucoma filtration surgery

Autor: R L, Beckman, S J, Sofinski, L J, Greff, D C, Oates, T J, Smith, R J, Simmons

Publikováno v: Ophthalmic surgery. 22(10)

The use of 5-Fluorouracil (5-FU) to inhibit scarring following filtration surgery has been hampered by corneal epithelial defects and their accompanying inflammation. This toxicity, which occurs during the crucial period in which the risk of bleb fai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::70c266449edbbc5ae491473d30a3524e
https://pubmed.ncbi.nlm.nih.gov/1961611

Zobrazit plný text záznamu

Optimal cost-effective designs of randomized phase II proof of concept trials and associated go-no go decisions

Autor: R. A. Beckman, C. Chen

Publikováno v: Journal of Clinical Oncology. 26:14669-14669

14669 Background: In oncology, the number of possible combinations of therapeutic agents far exceeds available patients for clinical proof of concept (POC) studies. We have investigated optimal cos...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6143bf501845165376e1725b75ce05a0
https://doi.org/10.1200/jco.2008.26.15_suppl.14669

Zobrazit plný text záznamu

Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP)

Autor: B. Foster, Z. Lang, Joel Picus, M. Mata, F. M. Chu, R. A. Beckman, C. Kopacynski, Robert Dreicer

Publikováno v: Journal of Clinical Oncology. 25:15595-15595

15595 Background: CNTO 95 has demonstrated preclinical antitumor activity through binding to multiple av integrins, resulting in growth inhibition indirectly through anti-angiogenic effects as well as directly by inhibiting tumor cell proliferation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c58411ee013413acdb9f8f475dea0958
https://doi.org/10.1200/jco.2007.25.18_suppl.15595

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání